Attached files

file filename
EX-32.1 - EX-32.1 - Mirati Therapeutics, Inc.mrtx-20201231xex321.htm
EX-31.2 - EX-31.2 - Mirati Therapeutics, Inc.mrtx-20201231xex312.htm
EX-31.1 - EX-31.1 - Mirati Therapeutics, Inc.mrtx-20201231xex311.htm
EX-21.1 - EX-21.1 - Mirati Therapeutics, Inc.exhibit211.htm
EX-10.38 - EX-10.38 - Mirati Therapeutics, Inc.employmentagreement-benhic.htm
EX-10.37 - EX-10.37 - Mirati Therapeutics, Inc.employmentagreement-danfag.htm
EX-10.36 - EX-10.36 - Mirati Therapeutics, Inc.townecentredrive-seventh.htm
EX-10.16 - EX-10.16 - Mirati Therapeutics, Inc.mrtx-20201231xex1016.htm
EX-4.5 - EX-4.5 - Mirati Therapeutics, Inc.mrtx-20201231xex45.htm
10-K - 10-K - Mirati Therapeutics, Inc.mrtx-20201231.htm

Exhibit 23.1


Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)Registration Statement (Form S-3 No. 333-227209) of Mirati Therapeutics, Inc.,
(2)Registration Statement (Form S-8 No. 333-218239) pertaining to the Amended and Restated 2013 Equity Incentive Plan of Mirati Therapeutics, Inc.,
(3)Registration Statements (Form S-8 Nos. 333-196487, 333-204720, and 333-233027) pertaining to the 2013 Equity Incentive Plan of Mirati Therapeutics, Inc.,
(4)Registration Statement (Form S-8 No. 333-189965) pertaining to the Amended and Restated Incentive Stock Option Plan, 2013 Equity Incentive Plan, and 2013 Employee Stock Purchase Plan of Mirati Therapeutics Inc., and
(5)Registration Statement (Form S-8 No. 333-235765) pertaining to the Mirati Therapeutics, Inc. Inducement Plan;

of our reports dated February 25, 2021, with respect to the consolidated financial statements of Mirati Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Mirati Therapeutics, Inc. included in this Annual Report (Form 10-K) of Mirati Therapeutics, Inc. for the year ended December 31, 2020.

/s/ Ernst & Young LLP

San Diego, California
February 25, 2021